CDKN2A and sarcoma: In a recent phase II study with palbociclib conducted in patients with different sarcoma types stratified based on the overexpression of CDK4 without CDKN2A overexpression using quantitative RT–PCR, the authors identified higher immunohistochemical scores of CDK4 protein expression associated with better survival.22